224 related articles for article (PubMed ID: 24851066)
1. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy.
Lee SA; Choi HM; Park HJ; Ko SK; Lee HY
Korean J Intern Med; 2014 May; 29(3):315-24. PubMed ID: 24851066
[TBL] [Abstract][Full Text] [Related]
2. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
da Silva PM
Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
[TBL] [Abstract][Full Text] [Related]
4. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
[TBL] [Abstract][Full Text] [Related]
5. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
[TBL] [Abstract][Full Text] [Related]
6. Is amlodipine more cardioprotective than other antihypertensive drug classes?
Park CG
Korean J Intern Med; 2014 May; 29(3):301-4. PubMed ID: 24851063
[No Abstract] [Full Text] [Related]
7. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
[TBL] [Abstract][Full Text] [Related]
8. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
[TBL] [Abstract][Full Text] [Related]
9. Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Zhang L; Yang J; Li L; Liu D; Xie X; Dong P; Lin Y
J Comp Eff Res; 2018 Jul; 7(7):651-660. PubMed ID: 29888950
[TBL] [Abstract][Full Text] [Related]
10. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication.
Jeffers BW; Robbins J; Bhambri R; Wajsbrot D
Am J Ther; 2015; 22(5):322-41. PubMed ID: 25738570
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
[TBL] [Abstract][Full Text] [Related]
13. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
[TBL] [Abstract][Full Text] [Related]
14. The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.
Wang W; Ma L; Zhang Y; Deng Q; Liu M; Liu L
J Hum Hypertens; 2011 Apr; 25(4):271-7. PubMed ID: 20445570
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
[TBL] [Abstract][Full Text] [Related]
16. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Poulter NR; Sever PS;
Lancet Neurol; 2010 May; 9(5):469-80. PubMed ID: 20227347
[TBL] [Abstract][Full Text] [Related]
17. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
20. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
